0000899243-22-007426.txt : 20220223 0000899243-22-007426.hdr.sgml : 20220223 20220223174534 ACCESSION NUMBER: 0000899243-22-007426 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20220218 FILED AS OF DATE: 20220223 DATE AS OF CHANGE: 20220223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ferneau Philip CENTRAL INDEX KEY: 0001814202 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39696 FILM NUMBER: 22665276 MAIL ADDRESS: STREET 1: 10 ALLEN STREET CITY: HANOVER STATE: NH ZIP: 03755 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Compass Therapeutics, Inc. CENTRAL INDEX KEY: 0001738021 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 BUSINESS PHONE: 617-500-8099 MAIL ADDRESS: STREET 1: 80 GUEST STREET CITY: BOSTON STATE: MA ZIP: 02135 FORMER COMPANY: FORMER CONFORMED NAME: Olivia Ventures, Inc. DATE OF NAME CHANGE: 20180419 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-18 0 0001738021 Compass Therapeutics, Inc. CMPX 0001814202 Ferneau Philip C/O COMPASS THERAPEUTICS, INC. 80 GUEST STREET, SUITE 601 BOSTON MA 02135 1 0 0 0 Stock Option (Right to Buy) 2.40 2022-02-18 4 A 0 30000 0.00 A 2032-02-17 Common Stock 30000 30000 D This option vests in substantially equal monthly installments over four years. The Reporting Person is a managing partner of Borealis Ventures. Pursuant to an agreement with Borealis Ventures, the Reporting Person is obligated to transfer any securities issued under any stock options or other awards, or the economic benefit thereof, to Borealis Granite Fund, L.P. and Vox Health Fund, L.P. Exhibit 24 - Power of Attorney /s/ Vered Bisker-Leib, attorney-in-fact 2022-02-23 EX-24 2 attachment1.htm EX-24 DOCUMENT
                                                                   Exhibit 24

                            LIMITED POWER OF ATTORNEY

        The undersigned hereby constitutes and appoints each of Thomas J.
Schuetz, Vered Bisker-Leib, Jonathan Anderman and Neil Lerner, signing singly,
and with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:

        (1)    execute for and on behalf of the undersigned, in the
undersigned's capacity as officer and/or director of Compass Therapeutics, Inc.
(the "Company"), from time to time the following U.S. Securities and Exchange
Commission ("SEC") forms: (i) Form ID, including any attached documents (such
as Update Passphrase Authentication), to effect the assignment of codes to the
undersigned to be used in the transmission of information to the SEC using the
EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of
Securities, including any attached documents; (iii) Form 4, Statement of
Changes in Beneficial Ownership of Securities, including any attached
documents; (iv) Form 5, Annual Statement of Beneficial Ownership of Securities
in accordance with Section 16(a) of the Securities Exchange Act of 1934, as
amended, and the rules thereunder, including any attached documents; (v)
Schedules 13D and 13G; and (vi) amendments of each thereof, in accordance with
the Securities Exchange Act of 1934, as amended, and the rules thereunder,
including any attached documents;

        (2)    do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to complete and execute any
such Form 3, 4 or 5, Schedule 13D or 13G, or any amendment(s) thereto and
timely file such form(s) with the SEC and any securities exchange, national
association or similar authority; and

        (3)    take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of
the undersigned pursuant to this Power of Attorney shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

        The undersigned hereby grants to each such attorney-in-fact, acting
singly, full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and purposes as
the undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees
to indemnify the attorneys-in-fact and the Company from and against any demand,
damage, loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorneys-in-fact.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file such forms with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact. This Power of Attorney supersedes any prior power
of attorney in connection with the undersigned's capacity as an officer and/or
director of the Company. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an employee
of the Company.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of February 22, 2022.


                                   /s/ Philip J. Ferneau
                                   -----------------------------------------
                                   Signature


                                   Philip J. Ferneau
                                   -----------------------------------------
                                   Print Name